Delisting risk
APM · NASDAQ · Biotechnology

Aptorum Group (APM)

Developing oncology, infectious disease, and diagnostic assets for unmet medical needs.

$8.26
At close−1.44 (−14.84%)

Breakdown13F · 13D/G · Form 4

101.8K ADS (1 ADS = 8 ordinary shares) as of Sep 3, 2026 · holders as of their latest filing

Two share counts disagree (101.8K in the company's Sep 3, 2026 report, 634.7K elsewhere); stakes use the report.

This company has 2 share classes; every stake here is a share of the whole company.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesEvidence
CGY Investments Limited (“CGYStrategic
17.59% of class, as filed13Dfiled Jul 11, 2019
Hudson Bay Capital Management LPInstitution
6.54% of class, as filed13Gfiled Feb 7, 2022
Kira S. SheinermanInsider
51.56% of class, as filed13Dfiled Jul 24, 2026
s: CGY Investments Limited (“CGY Investments”)Strategic
17.59% of class, as filed13Dfiled May 8, 2019
s: Ian Huen (“Ian”)Insider
69.25% of class, as filed13D/Afiled Jun 1, 2021

13D/13G — an ownership statement filed at 5% or more

Institutions13F

No 13F holders on record.

Ownership statements13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Kira S. Sheinerman51.56%1.52M13DJul 24, 2026

Insider tradesForm 4

Latest trades

Nothing filed in the last 12 months.

CongressHouse and Senate disclosures

Not reported.